Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Novo Nordisk ( (NVO) ) just unveiled an update.
On February 6, 2025, Novo Nordisk board members, executives, and associated persons engaged in transactions involving the sale of company shares, as disclosed in compliance with market abuse regulations. Executive Vice President, Marcus Schindler, was involved in the sale of 40,000 shares at a price of DKK 620.26 per share, totaling DKK 24,810,329. This trading activity, conducted on Nasdaq Copenhagen, is part of the company’s transparency efforts and could impact stakeholder perceptions and market dynamics.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases. The company pioneers scientific breakthroughs, expands access to medicines, and works towards curing diseases, primarily in the realm of diabetes. Novo Nordisk employs about 72,000 people across 80 countries, marketing its products in approximately 170 countries. Its B shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
YTD Price Performance: -0.40%
Average Trading Volume: 8,054,584
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $391.9B
For detailed information about NVO stock, go to TipRanks’ Stock Analysis page.
